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Summary
 
Characterization of cytolytic T lymphocyte (CTL) responses to tumor antigens has been im-
peded by a lack of direct assays of CTL activity. We have synthesized reagents (“tetramers”)
that specifically stain CTLs recognizing melanoma antigens. Tetramer staining of tumor-infil-
trated lymph nodes ex vivo revealed high frequencies of tumor-specific CTLs which were an-
tigen-experienced by surface phenotype. In vitro culture of lymph node cells with cytokines
resulted in very large expansions of tumor-specific CTLs that were dependent on the presence
of tumor cells in the lymph nodes. Tetramer-guided sorting by flow cytometer allowed isola-
tion of melanoma-specific CTLs and confirmation of their specificity and their ability to lyse
autologous tumor cells. Our results demonstrate the value of these novel reagents for monitor-
ing tumor-specific CTL responses and for generating CTLs for adoptive immunotherapy.
These data also indicate that strong CTL responses to melanoma often occur in vivo, and that
the reactive CTLs have substantial proliferative and tumoricidal potential.
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he recent molecular characterization of tumor anti-
gens recognized by MHC class I–restricted human
CTLs has opened up new possibilities for the immunother-
apy of cancer. It is now well established that human tumor
cells, notably cutaneous melanoma, may express multiple
CTL-defined antigens that are shared among tumors, pro-
viding the prospect for generic vaccines applicable to large
subsets of cancer patients (1, 2). Hence, numerous clinical
trials are underway aimed at inducing vigorous CTL re-
sponses against defined tumor antigens. However, further
progress in understanding natural or vaccine-induced CTL
responses to tumor antigens has been prevented by the lack
of direct assays of CTL activity. Previous assays for detec-
tion of antigen-specific CTLs have depended on their abil-
ity to proliferate extensively and acquire lytic activity, or to
release relatively large amounts of cytokine (3), such that
accurate quantification of these cells has not been possible.
The necessity of stimulating CTLs with antigen in order to
detect them has also prevented characterization of their
phenotype in vivo. Recently, tetrameric arrays of soluble
class I MHC–peptide complexes (“tetramers”) have been
used to identify antigen-specific CTLs (4), and techniques
for detecting and isolating low-frequency CTLs using these
reagents have been developed and validated (5). We report
here the first analyses of patient samples using tetramers
incorporating melanoma-derived antigenic peptides. These
reagents were used to directly enumerate and phenotype
melanoma-specific CTLs ex vivo from both metastatic
lesions and peripheral blood, using multiparameter flow
cytometry.
 
Materials and Methods
 
Tissues and Cells.
 
Melanoma patients subjected to therapeutic
surgical LN resection were selected for this study on the basis of
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HLA-A2 antigen expression as assessed by flow cytometry of
PBMC stained with allele-specific mAb BB7.2 (6). Individual
LNs collected by surgical dissection were dissociated to single cell
suspensions in sterile RPMI 1640 supplemented with 10% FCS.
Melanoma cell lines were obtained from the adherent fraction of
LN cells from all patients in Table 1, except LAU 132, LAU 181,
and LAU 240, resulting after 2 h incubation at 37
 
8
 
C of an aliquot
of LN cell suspension. The rest of the LN cell suspension was cryo-
preserved in RPMI 1640, 40% FCS, 10% DMSO. Vials containing
5–10 
 
3 
 
10
 
6
 
 cells were stored in liquid nitrogen. Control LNs (a
total of 12 LNs) were obtained from 8 nonmelanoma cancer pa-
tients (Table 2). Half of each control LN was processed as described
above to generate LN cell suspensions. The rest of each control LN
was submitted to anatomopathological examination. T2 cells were
maintained in IMDM supplemented with 10% FCS. Cells derived
from each LN were kept as separate, individual batches of cryopre-
served cells. PBMC were separated from heparinized blood by centri-
fugation over Ficoll-Paque (Amersham Pharmacia Biotech, Upp-
sala, Sweden), washed three times, and cryopreserved as described
above. CTL clones specific for Melan-A and tyrosinase were de-
rived from patients LAU 203 and LAU 132, respectively, and the
influenza matrix–specific CTL clone was from a healthy donor and
maintained in continuous culture as described elsewhere (7, 8).
 
Tetramers.
 
Complexes were synthesized as described (4, 9). In
brief, purified HLA heavy chain and 
 
b
 
2-microglobulin (
 
b
 
2M)
 
1
 
were synthesized using a prokaryotic expression system (pET;
R&D Systems, Inc., Minneapolis, MN). The heavy chain was
modified by deletion of the transmembrane cytosolic tail and
COOH-terminal addition of a sequence containing the BirA en-
zymatic biotinylation site. Heavy chain, 
 
b
 
2M, and peptide were
refolded by dilution. The 45-kD refolded product was isolated by
fast protein liquid chromatography and then biotinylated by re-
combinant BirA (Avidity, Denver, CO) in the presence of biotin,
adenosine 5
 
9
 
-triphosphate, and Mg
 
2
 
1
 
 (all from Sigma Chemical
Co., St. Louis, MO). Streptavidin–PE conjugate (Sigma Chemical
Co.) was added in a 1:4 molar ratio, and the tetrameric product
was concentrated to 1 mg/ml.
 
mAbs.
 
Anti-CD8
 
FITC,PerCP
 
, anti-CD3
 
PerCP
 
, and anti-CD45-
RA
 
FITC
 
 were obtained from Becton Dickinson (San Jose, CA).
Anti-CD45RO
 
FITC
 
 was from DAKO Corp. (Carpinteria, CA).
 
Flow Cytometry Immunofluorescence Analysis.
 
Thawed LN cell
suspensions were cultured individually for 16–20 h in IMDM
supplemented with 0.55 mM Arg, 0.24 mM Asn, 1.5 mM Gln,
10% pooled human A
 
1
 
 serum (complete medium), supplemented
with recombinant human (rh)IL-2 (100 U/ml) and rhIL-7 (10
ng/ml). Cells (0.5–1 
 
3 
 
10
 
6
 
) were stained with tetramers and
FITC and PerCP mAb conjugates in 50 
 
m
 
l of PBS, 2% BSA, and
0.2% azide for 40 min at 4
 
8
 
C. Cells were washed once in the
same buffer and analyzed immediately in a FACSCalibur
 
Ò
 
 (Bec-
ton Dickinson). Data acquisition and analysis were performed us-
ing CellQuest
 
Ô
 
 software. CD8
 
1
 
 lymphocytes were purified
from PBMC in two rounds of positive selection by magnetic cell
sorting using a miniMACS
 
Ò
 
 device (Miltenyi Biotec Inc., Sunny-
vale, CA). The resulting cells which were 
 
.
 
98% CD3
 
1
 
CD8
 
1
 
were stained for flow cytometry analysis as described above.
 
Chromium-release Assay.
 
Antigen recognition was assessed
using target cells (T2 or melanoma) labeled with 
 
51
 
Cr for 1 h at
37
 
8
 
C and washed two times. Labeled target cells (10
 
3
 
 cells in 50 
 
m
 
l)
were then added to varying numbers of effector cells (50 
 
m
 
l) in
V-bottomed microwells in the presence or absence of 1 
 
m
 
g/ml of
antigenic peptide (50 
 
m
 
l). The effector cells were preincubated
for at least 20 min at 37
 
8
 
C with unlabeled K562 cells (5 
 
3
 
 10
 
4
 
/
well) to eliminate nonspecific lysis due to NK-like effectors.
Chromium release was measured in supernatant (100 
 
m
 
l) har-
vested after 4 h incubation at 37
 
8
 
C. The percent specific lysis was
calculated as described (7).
 
Analysis of mRNA Expression.
 
Total RNA was extracted from
frozen LNs by the guanidinium isothiocyanate/cesium chloride
procedure. cDNA was synthesized as described (10). Aliquots
corresponding to 100 ng of starting RNA were amplified by 30
cycles of PCR using Melan-A–specific primers (10) and the tyro-
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
2M, 
 
b
 
2-microglobulin; LDA, limiting
dilution assay; NLN, non–tumor-infiltrated lymph node; rh, recombinant
human; RT, reverse transcription; TILN, tumor-infiltrated lymph node.
 
Table 1.
 
Clinical Parameters of Metastatic Melanoma Patients
 
Patient
 
*
 
Age Tumor stage (AJCC) LN dissection Disease interval
 
‡
 
Previous treatment Survival status 1998
 
yr yr yr
 
LAU 50 65 pT4aN2cM0 1 N
 
1
 
/14 N 5 ILP (TIM) 8, tumor free
LAU 56 39 pT4aN2cM0 2 N
 
1
 
/17 N 10 ILP (TIM) 11, tumor free
LAU 132 35 pT3aN2aM0 15 N
 
1
 
/16 N 1.3 ILP (M) IFN-
 
a
 
, 1 yr
 
§
 
3, tumor free
LAU 181 42 pT4N2M0 2 N
 
1
 
/14 N 2 Surgery 3, tumor free
LAU 203 66 pTxN2cM0
 
$
 
3 N
 
1
 
5 Surgery 7, tumor free
LAU 233 75 pT4N2cM0 6 N
 
1
 
/10 N 2 None 4, tumor free
LAU 240 65 pTxN2cM0 11 N
 
1
 
/15 N
 
,
 
1 None 1, PD
LAU 253 61 pT3aN2M0 18 N
 
1
 
/27 N 1.3 Surgery 4, PD
LAU 267 45 pT4aN2cM0 1 N
 
1
 
,
 
1 IFN-
 
a
 
, 
 
,
 
1 yr 1, PD
 
AJCC, 
 
American Joint Committee on Cancer.
 
 ILP (TIM)
 
, Isolated limb perfusion with TNF-
 
a
 
 (4 mg), IFN-
 
g
 
 (0.2 mg), and melphalan. 
 
ILP (M)
 
,
Isolated limb perfusion with melphalan alone. 
 
N
 
, Node. 
 
PD
 
, Progressive disease.
 
*
 
All metastatic nodes included in this series, except that from LAU 56, were found to express Melan-A and tyrosinase mRNA by RT-PCR.
 
‡
 
Time elapsed between diagnosis of primary melanoma and surgical resection of LNs analyzed in this study.
 
§
 
IFN-
 
a
 
 administered as adjuvant therapy intermediate high dose regimen. 
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sinase-specific primers 
 
HTYR1 
 
and
 
 HTYR2
 
 (11). Aliquots of
each reaction were run on a 2% agarose gel and visualized by
ethidium bromide fluorescence. To verify RNA integrity, a
21-cycle PCR assay with primers specific for 
 
b
 
-actin was carried
out in each case. To increase sensitivity in the detection of tumor
cells in those LNs macroscopically uninfiltrated, the PCR prod-
ucts were further analyzed by Southern blotting using internal
cDNA fragments as probes. Alternatively, PCR was performed
with 40 cycles. The detection limit was approximately equivalent
to 10 tumor cells per 10
 
6
 
 lymphocytes, as determined from titra-
tion experiments with the melanoma cell line SK23-MEL.
 
Results
 
Generation and Characterization of A2/Melanoma Peptide
Tetramers.
 
Tetramers were synthesized around two anti-
genic peptides recognized by HLA-A*0201–restricted CTLs,
both of which derive from melanocyte lineage–specific
proteins. One peptide was the natural tyrosinase 368–376
epitope (the N370D variant, YMDGTMSQV, generated
by antigen processing [12]); the other was a modification of
the Melan-A 26–35 epitope (7). This modified epitope,
ELAGIGILTV, carrying a substitution of Ala for Leu at
position 2 from the NH
 
2
 
 terminus (hereafter A27L), forms
relatively stable complexes with HLA-A2 and is a more
potent immunogen than the natural Melan-A peptide (8).
MHC class I–peptide complexes were prepared essentially
as described (4, 5, 9), by refolding expressed HLA-A*0201
heavy chain (hereafter A2) and 
 
b
 
2M around the peptides.
The heavy chain had been engineered with a COOH-ter-
minal signal sequence for the biotinylating enzyme BirA, so
 
Table 2.
 
Enumeration of A2/Tumor Antigen Tetramer Binding Lymphocytes in Ex Vivo LN Cells Draining Nonmelanoma Tumors
 
LN no. Patient Age Carcinoma Stage Type of LN
 
*
 
HLA-A2
 
‡
 
% CD8
 
1
 
§
 
% CD8
 
1
 
 tetramer
 
1
 
i
 
yr
 
1 LAU 292 75 Bladder BCGitis
 
¶
 
Right ilioobturator NLN
 
1
 
2.2
2.7
0.18
0.08
2 LAU 293 46 Breast pT2N0Mx Low axillary NLN
 
2
 
9.7
7.2
0.18
0.13
3 LAU 293 External axillary NLN
 
2
 
9.1
8
0.17
0.2
4 LAU 295 61 Renal cell pT2N0Mx Right pararenal NLN
 
2
 
5.6
6
0.11
0.14
5 LAU 296 75 Lung pT1N1Mx Intertracheal NLN
 
2
 
8.5
8.2
0.09
0.18
6 LAU 296 Right paratracheal NLN
 
2
 
6.5
7.3
0.11
0.11
7 LAU 297 75 Colon pT4N0M1 Left colon NLN
 
2
 
3.5
4.6
0.08
0.06
8 LAU 297 Paraaortic NLN 2 5.4
5.8
0.04
0.04
9 LAU298 49 Bladder pT4aN2 Left TILN 1 3.2
3.6
0.1
0.14
10 LAU 298 Right NLN 1 6 0.11
11 LAU 299 68 Prostate pT3bN0 Left ilioobturator NLN 1 4.4 0.11
12 LAU 301 Gastric pT3N0Mx Satellite NLN 1 3.1
3.3
0.08
0.04
A cut-off value of 0.25 was calculated as the mean of a total of 22 determinations (0.11) of CD81 tetramer1 LN cells from 12 LNs analyzed from
nonmelanoma tumors, plus 3 SD (0.14).
*Based on pathology examination of a fragment of the same LN.
‡An aliquot of the LN cell suspension was stained with HLA-A2–specific mAb BB7.2.
§LN cell suspensions were cultured overnight in complete medium supplemented with rIL-2 and rIL-7. Aliquots of the cell suspension were ana-
lyzed by two-color flow cytometry with anti-CD8PerCP and A2/Melan-A tetramers. The percentage of CD81 cells was calculated relative to all cells
included in the live cell gate.
iLive CD81 LN cells were electronically gated, and the percentage of tetramer1 cells was calculated by setting a region similar to those used in Fig.
2 A. The determinations were generally performed in duplicate except in those LNs in which there were insufficient numbers of cells.
¶Subacute granulomatous cystitis after therapy with BCG. No residual tumor was found upon anatomopathological examination of resected tissues.
The primary tumor had been resected 2 yr earlier by endoscopy.1644 Monitoring Tumor-specific Cytolytic T Lymphocytes with Tetramers
complexes purified by FPLC were biotinylated and bound
to PE-labeled streptavidin at a 4:1 ratio to form A2/Melan-A
and A2/tyrosinase tetramers. A2/matrix tetramer based on
the HLA-A*0201–restricted influenza matrix protein peptide
58–66 (GILGFVFTL) was used as a control reagent (5).
Monoclonal CTL populations were used to test the abil-
ity of these tetramers to specifically label cells expressing
the appropriate cognate TCR. As shown in Fig. 1 A, tet-
ramers uniformly stained CTL clones in a specific fashion,
generating fluorescent signal two orders of magnitude higher
than background. The specificity of staining correlated per-
fectly with the specificity of lytic activity displayed by the
CTL clones against chromium-labeled target cells pulsed
with their cognate peptide (Fig. 1 B). It is noteworthy that
the Melan-A–specific CTL clone used in these experiments
recognized both the unmodified peptide (data not shown)
and the A27L-modified peptide, indicating that the A2/
Melan-A tetramers carrying the modified A27L peptide
stain cells recognized the natural peptide. Further confir-
mation that the two peptides are interchangeable was ob-
tained by demonstrating that a tetramer synthesized around
the unmodified peptide also stained the CTL clone (data
not shown).
Enumeration of Melan-A– and Tyrosinase-specific CTLs in
Tumor-infiltrated LNs. Tissue and/or blood samples were
obtained from nine HLA-A*0201 patients with metastatic
melanoma, whose clinical characteristics are presented in
Table 1. Tumor-infiltrated LNs (TILNs) were surgically
excised and separated to single cell suspensions which were
immediately stained or cryopreserved. In two cases, LNs
which were not macroscopically infiltrated with tumor
(NLNs) were also surgically excised from the same anatom-
ical region, and processed to single cells. TILNs and NLNs
were examined for the expression of tumor antigens by re-
verse transcription (RT)-PCR. All TILNs except one
(from patient LAU 56) contained tumor cells expressing
the Melan-A and tyrosinase antigens (Table 3). One of the
NLN preparations (LAU 267) was negative for both tumor
antigens, whereas the second (LAU 181) was weakly posi-
tive for Melan-A, suggesting the presence of a small num-
ber of tumor cells infiltrating the node (Table 3).
Initially, four TILNs from three patients were thawed,
cultured overnight in cytokine-supplemented medium,
then triple-stained with anti-CD8 mAb, anti-CD3 mAb,
and either the A2/Melan-A or the A2/tyrosinase tetramer.
Tetramer1 cells were confined to the CD81 compartment
of CD31 cells, as expected for CTLs (Fig. 2 A). When cells
were gated for staining similar to that of Melan-A–specific
clones, frequencies of A2/Melan-A tetramer1 cells were
surprisingly high, 1.8, 0.42, 0.92, and 0.22%, respectively,
of CD31CD81 cells, i.e., a frequency of CTLs between 1
in 50 and 1 in 500 CD81 LN cells. The frequency of A2/
Figure 1. Fluorescent soluble HLA-A2/
antigenic peptide tetramers specifically stain
cloned CTLs. (A) Three HLA-A2/peptide
tetramers, incorporating Melan-A26–35 A27L
analogue, tyrosinase368–376, and influenza
matrix58–66 peptides, were tested for their
ability to stain CTL clones LAU 203/47
specific for Melan-A26–35, LAU 132/2 spe-
cific for tyrosinase368–376, and NM 17 spe-
cific for influenza matrix58–66. (B) The speci-
ficity of peptide antigen recognition by the
three CTL clones was assayed on chro-
mium-labeled T2 target cells sensitized
with either Melan-A26–35 ( open triangles),
tyrosinase368–376 (filled triangles), or influenza
matrix58–66 (filled circles) at the indicated lym-
phocyte to target cell ratios.1645 Romero et al.
Melan-A tetramer1 CD81 cells in LN cells from a normal
individual stained under similar conditions was ,0.05%
(not shown). To determine more precisely the levels of
nonspecific tetramer staining of CD81 LN cells, a series of
12 LNs draining randomly selected nonmelanoma tumors
were also analyzed in a similar fashion. The levels of CD8/
tetramer double positives were in average 0.11% of CD81
LN cells, with a standard deviation of 0.05% (Table 2).
Table 3. Enumeration of A2/Tumor Antigen Tetramer Binding Lymphocytes in Ex Vivo or Short-term Cultured LN Cells from HLA-A21 
Melanoma Patients
Melanoma patient Type of LN
PCR
Exp. no.
Days
in culture*
% CD81 in
lymphocyte gate‡
% tetramer1 in CD81 LN cells
Melan-A Tyrosinase Melan-A Tyrosinase
LAU 50 TILN 11 21.2 1 12.3 0.94 0.08
LAU 56 TILN 22 21.2 1 4.8 0.64 0
LAU 132 TILN 11 21.2 21 93 3.67 0.63
LAU 181 NLN 123.3 1 11.8 0.29
3.3 1 11.8 0.23
18.5 1 13.7 0.35
18.5 1 13.8 0.30
TILN 113.3 1 41 0.51
3.3 1 41.9 0.48
18.5 1 41.2 0.46
18.5 1 43.3 0.49
LAU 203 TILN 11 21.2 16 89 12.00 0.05
LAU 233 TILN 11 21.2 12 76 21.10 0.48
LAU 240 TILN-1 11 21.2 1 15.6 0.82 0.03
TILN-2 11 21.2 1 4.3 0.52 0
LAU 253 TILN-1 11 23.7 1 13.5 1.05 0.14
23.7 1 14.6 1.21
TILN-2 11 23.7 1 10.2 0.78
23.7 1 10.2 0.81
LAU 267 NLN 224.3 0 11.2 0.22
4.3 0 11.4 0.12
18.5 1 12.6 0.21
18.5 1 12.9 0.30
TILN-1 114.3 0 9.7 0.45
4.3 0 9.9 0.40
18.5 1 10.4 0.45
18.5 1 10.1 0.47
1 10.4 0.62
TILN-2 114.3 0 10.3 3.27
4.3 0 10.8 3.52
18.5 1 11.8 3.53
18.5 1 11.9 3.14
18.5 1 11.8 3.70
NLN, Macroscopically normal LN. Exp., Experiment.
*LN cell suspensions were cultured in complete medium supplemented with rIL-2 and rIL-7 at 37°C for the indicated number of days. In the assays
where d 5 0, fresh LN cells were analyzed immediately after cell suspension preparation. In the assays where d 5 1, thawed LN cells were cultured
for 16–20 h before analysis.
‡Aliquots of TILNs or NLNs were analyzed by three-color flow cytometry after staining with anti-CD3 or anti-CD45RA, or anti-CD45RO, anti-
CD8, and either A2/Melan-A or A2/tyrosinase tetramers as in Fig. 2 A. CD81 LN cells were gated, and the percentage of tetramer1 cells was deter-
mined by setting a region as in Fig. 2 A. CD31CD82 LNs were also analyzed on a separate gate, and the percentage of tetramer1 cells varied
between 0.00 and 0.06% of gated cells, with one single exception where this percentage was 0.22% for cells of patient LAU 233 stained with the A2/
Melan-A tetramers (not shown).1646 Monitoring Tumor-specific Cytolytic T Lymphocytes with Tetramers
When these LNs were segregated into HLA-A21 (5 LNs
and a total of 8 stainings) and HLA-A22 (7 LNs and a total
of 14 stainings), the mean percentages of CD8/tetramer
double positive LN cells detected were not significantly
different (0.11 6 0.04 and 0.12 6 0.05, respectively). It
can be concluded from this analysis that the lower detec-
tion limit with A2/Melan-A tetramers is z0.2% of CD81
LN cells (mean 1 3 SD 5 0.25; Table 2). Finally, frequen-
cies of A2/tyrosinase tetramer1 CTLs in the melanoma
TILNs were ,0.05% in the four TILNs (illustrated for
LAU 50, Fig. 2 A).
Frequencies of antigen-specific CTLs derived from tet-
ramer staining were compared with frequencies generated
using the limiting dilution assay (LDA), which detects
CTLs with high proliferative potential. LDA of selected
TILNs showed that the frequencies of Melan-A–specific
CTLs were consistently lower (5–20-fold) than those ob-
tained through direct staining with tetramers (data not
shown). This discrepancy is consistent with data obtained
for influenza- and HIV-specific CTLs, where frequencies
reported using tetramer staining have been approximately
one order of magnitude higher than those reported for
LDA (5, 9), and confirms that tetramers can stain CTLs
which are potent antigen-specific effector cells despite lim-
ited proliferative potential (5).
Phenotype Analysis of Melan-A–specific CTLs in TILNs and
Peripheral Blood. To establish whether the A2/Melan-A
tetramer1 cells in infiltrated LNs had previously been
exposed to antigen, LN cells were triple stained ex vivo
with A2/Melan-A tetramer, anti-CD8 mAb, and anti-
CD45RO mAb, the latter recognizing a stable marker of
antigen-experienced cells (13). Two melanoma patients
were studied, and one or two TILNs were compared with
adjacent NLNs. Compared with the latter, the frequencies
Figure 2. Direct identification of HLA-A2/tumor peptide antigen tet-
ramer binding lymphocytes in TILNs. (A) Four TILNs obtained from three
HLA-A2 melanoma patients were stained, after overnight culture, with
either A2/Melan-A26–35 A27L or A2/tyrosinase368–376 tetramers together
with anti-CD3PerCP mAb and anti-CD8FITC mAb. Dot plots are shown for
gated CD81 LN cells. (B) Ex vivo A2/Melan-A tetramer1 TILNs have an
activated phenotype. Cell suspensions prepared from normal (NLN) or
metastatic (TILN) LNs from patient LAU 267 were directly analyzed by
three-color flow cytometry using anti-CD8PerCP mAb, A2/Melan-A tet-
ramers, and either anti-CD45RAFITC mAb (top) or anti-CD45ROFITC mAb
(bottom). Dot plots are shown for gated CD81 LN cells. (C) Enumeration
and phenotype of tetramer1 cells in ex vivo circulating lymphocytes.
Highly homogeneous CD81 lymphocyte populations (.98%) were ob-
tained from PBMC of patient LAU 267, or from a healthy donor (HD), by
two rounds of positive selection with magnetic cell sorting. The lympho-
cyte preparation was then stained with A2/Melan-A or A2/influenza
matrix tetramers and anti-CD45RACychrome and analyzed immediately by
flow cytometry. The histograms on top of dot plots show the intensity of
the fluorescence signal on the FL-3 channel of gated Melan-A/tetramer1 or
influenza tetramer1 lymphocytes. (D) Summary of phenotyping data
obtained from NLNs, TILNs, and PBMC from patients LAU 181 and LAU
267. The LN cell suspensions were stained either immediately after cell
suspension preparation (LAU 267) or after overnight culture of previously
cryopreserved uncultured LN cells (LAU 181) with either anti-
CD45RAFITC or anti-CD45ROFITC in combination with anti-CD8PerP and
A2/Melan-A tetramers. The results for the CD45RA and CD45RO triple
staining of NLNs and TILN-2 from LAU 267 are illustrated in B. Ad-
ditionally, PBMC available from the same time of the LN dissection from patient LAU 267 were stained as illustrated in C. The percentages of either
CD45RO1 or CD45RA2 in gated A2/Melan-A tetramer1 LN cells were calculated with CellQuestÔ software.1647 Romero et al.
of A2/Melan-A tetramer1 CD81 cells were increased (up
to 11-fold) in all three TILNs (Fig. 2 B, and Table 3). In
the TILNs from patient LAU 181 and TILN-2 from pa-
tient LAU 267, 95% of the A2/Melan-A tetramer1 CD81
cells were CD45RO1 and CD45RA2 (Fig. 2, B and D).
By contrast, in the NLNs from patient LAU 267, the vast
majority of A2/Melan-A tetramer1 CD81 cells detected
were neither CD45RO1 nor CD45RA2 (Fig. 2, B and D).
Hence, an expanded population of A2/Melan-A tetramer1
CD81 cells was identified in TILNs compared with NLNs,
and these cells had the phenotype of antigen-experienced
cells, providing direct evidence that an antigen-specific
immune response had been triggered in these patients. In-
terestingly, fewer tetramer1 CD81 cells in TILN-1 from
patient LAU 267 were CD45RO1/CD45RA2 than in
TILN-2 (z55 vs. 95%, Fig. 2 D). TILN-2 showed a much
larger expansion of A2/Melan-A tetramer1 CD81 cells
than TILN-1 (11-fold vs. 1.8-fold); therefore, a greater ex-
pansion in these CTLs correlated with a more substantial
shift towards the CD45RO1/CD45RA2 phenotype. Sim-
ilarly, the relatively higher proportion of CD45RO1/
CD45RA2 tetramer1 cells in the NLNs from patient LAU
181 compared with the NLNs from patient LAU 267 (Fig.
2 D) may reflect the presence of small numbers of tumor
cells in the LAU 181 NLNs which were absent from the
LAU 267 NLNs, as determined by RT-PCR.
The results of multiple flow cytometry analyses of indi-
vidual LNs performed with Melan-A or tyrosinase tetra-
mers are compiled in Table 3. It is noteworthy that the pro-
portions of CD81 lymphocytes staining positively with
A2/Melan-A tetramers calculated from independent deter-
minations, in the same assay or even in two independent
assays, using the same batch of cryopreserved LN cells were
generally in good agreement (LAU 181, LAU 253, and
LAU 267; Table 3). Moreover, the short period of over-
night culture in the presence of cytokines used before
staining of cryopreserved LN cells did not seem to signifi-
cantly alter the numbers of tetramer1 CD81 LN cells or
their CD45 isoform phenotype (LAU 267; Table 3, and
data not shown).
To see whether the presence of a strong Melan-A–
specific CTL response in TILNs could be detected in the
periphery, PBMC from patient LAU 267 were stained
with tetramers. A2/Melan-A tetramer1 CD81 cells could
be detected in peripheral blood after enrichment for CD81
cells, but only a minority (z16%) of these cells were
CD45RA2 (Fig. 2 C). In contrast, essentially all A2/influ-
enza matrix tetramer1 CD81 cells in the blood of a normal
individual were CD45RA2 (Fig 2 C), consistent with previ-
ous antigen exposure. Hence, the marked bias towards the
CD45RO1/CD45RA2 phenotype observed in Melan-A–
specific CTLs in TILNs was specific to the site of tumor
contact.
Expansion of Melan-A– and Tyrosinase-specific CTLs from
TILNs. Since CTLs which have recently been exposed to
their cognate antigen proliferate when exposed to cyto-
kines such as IL-2, it might be predicted that some mela-
noma-specific CD45RO1/CD45RA2 CTLs in TILNs
would proliferate during in vitro culture in the presence
of such cytokines. Indeed, when TILN cell suspensions
were cultured for 2–3 wk in the presence of rhIL-2 and
rhIL-7, substantial populations of A2/Melan-A tetramer1
CD31CD81 cells emerged, accounting for up to one CTL
in five CD81 cultured cells, while smaller populations of
A2/tyrosinase tetramer1 cells were also seen (Table 3). The
massive expansion of A2/Melan-A tetramer1 cells was fol-
lowed over time in samples from a fifth patient, LAU 181.
TILN and NLN cells from this patient were cultured in
parallel with cytokines for 21 d, and stained at three time
points during culture. A large expansion of A2/Melan-A
tetramer1 CD31CD81 cells was observed in the cultures of
TILN cells, but not in cultures of NLN cells (Fig. 3 A). Cal-
culations of the absolute numbers of tetramer1 CD31CD81
cells indicated that these cells had expanded 860-fold by
day 15 (equivalent to at least 9 rounds of cell division), and
2,560-fold by day 21 (at least 11 cell divisions). In contrast,
in the parallel culture of NLN cells, A2/Melan-A
tetramer1 CD31CD81 cells had expanded at most fourfold
by day 21. The possibility that small numbers of tumor cells
may have infiltrated this sample, as suggested by RT-PCR
for Melan-A mRNA, may explain the presence of small
numbers of Melan-A–specific CTLs in this NLN culture.
Functional Evidence that Tetramer1 CD31CD81 Cells from
TILNs Are Antigen-specific CTLs. TILNs cultured in cyto-
kines were used to confirm the functional specificity of
tetramer1 cells. Cultured populations containing a substan-
tial proportion of A2/tetramer1 CD31CD81 cells were
sorted according to tetramer staining, to produce highly
homogeneous subpopulations that were either tetramer1 or
tetramer2 (as shown in Fig. 3 B). These subpopulations
were subsequently tested for their ability to lyse target cells
pulsed with various HLA-A*0201–restricted melanoma
antigen peptides. A2/Melan-A tetramer1 CD31CD81 cells
lysed targets pulsed with the natural Melan-A peptide, but
not with peptides from other antigens, whereas the A2/
Melan-A tetramer2 cells were not able to lyse targets
pulsed with any of the peptides, including Melan-A (Fig. 3
C). These data provide direct evidence that A2/Melan-A
tetramer1 CD31CD81 cell populations derived from TILNs
contain HLA-A2–restricted CTLs recognizing peptide
Melan-A 26–35. In addition, the cells were able to lyse an
autologous melanoma cell line generated from the same
TILN (Fig. 3 D), thus confirming their tumoricidal capac-
ity. Interestingly, the Melan-A tetramer1 subpopulation
displayed higher lytic capacity per cell than the unsorted
population, although tumoricidal CTLs (which presumably
recognize other antigens) were also detected in the tetra-
mer2 subpopulation (Fig. 3 D).
Discussion
This study demonstrates, for the first time, the quantifi-
cation and phenotyping of tumor-specific CTLs in meta-
static tumors directly ex vivo. Our results show that tumor-
specific CTLs are often present in high numbers in TILNs,
are antigen-experienced, and are capable of massive expan-1648 Monitoring Tumor-specific Cytolytic T Lymphocytes with Tetramers
sion when exposed to the appropriate cytokines, generating
highly tumoricidal CTL populations.
Previous studies (7, 8, 14, 15) have provided indirect ev-
idence for the presence of CTLs infiltrating tumor sites, but
it had not previously been possible to directly identify and
enumerate such cells. Prolonged tissue culture of cells from
melanoma metastases produced cell lines that were tumori-
cidal in vitro, could be administered to patients with some
clinical benefit (16), and were eventually instrumental in
the identification of molecularly defined tumor antigens.
However, little was known about the nature of any im-
mune response generated in patients, since CTLs specific
for tumor antigens could not be identified ex vivo, pre-
cluding accurate estimates of their frequency or assessment
of their phenotype. Even in long-term polyclonal CTL
lines generated from patients, accurate assessment of anti-
gen-specific cytolytic activity by chromium-release assay
has often been confounded by high nonspecific lysis due to
lymphokine activation of other lymphocytes.
The use of fluorescent class I MHC–peptide complexes
allowed us to confirm what has long been suspected but
technically impossible to address, namely that at least some
patients with metastatic melanoma develop a substantial
CTL response against their tumor. Indeed, the frequency
of Melan-A–specific CTLs in freshly isolated TILNs ex
vivo was found to be as high as 1 in 30 CD31CD81 cells, a
frequency much higher than that reported previously using
less sensitive techniques. Given that we have only analyzed
two known tumor epitopes from a list of tens of defined
epitopes, and perhaps many more epitopes as yet unknown,
it seems likely that tumor-specific CTLs may account for a
substantial proportion of the total CD31CD81 cells present
in TILNs.
It is also noteworthy that Melan-A–specific CTL popu-
lations purified from TILNs by flow cytometry sorting
were functionally extremely effective in killing both pep-
tide-pulsed cells and autologous tumor cells. Similar results
were obtained with sorted A2/tyrosinase tetramer1 TILN
cells (data not shown). In contrast to previous methods
used for generating CTLs for adoptive immunotherapy,
tetramer-based sorting methods do not require peptide
stimulation for generation and thus may circumvent the
production of low-avidity CTLs due to prolonged expo-
sure to cognate peptide (17). Clearly, isolation of mela-
Figure 3. Functional activity of TILNs sorted
according to their tetramer staining phenotype
correlates with antigen specificity. (A) Cell sus-
pensions prepared from a metastatic (TILN) and
a normal (NLN) LN excised from the same ana-
tomical region of patient LAU 181 were cul-
tured in complete medium supplemented with
rIL-2 and rIL-7, and aliquots of cells were triple
stained with anti-CD8FITC mAb, anti-CD3PerCP
mAb, and A2/Melan-A tetramers either after
overnight (top), 15 d (middle), or 21 d (bottom) of
culture. A2/Melan-A tetramer versus CD3 dot
plots are shown for gated CD81 live lympho-
cytes, and the percentage of cells staining posi-
tively with the tetramers is indicated. (B) The
TILN population from patient LAU 233 was an-
alyzed by three-color cytometry, after 12 d in
culture with recombinant cytokines only, using
the same reagents as in A, and the staining
profiles are shown (top, Unsorted TILN). CD31
CD81 TILNs were sterile sorted into A2/
Melan-A tetramer1 and tetramer2 populations.
After expansion for 2 wk in the presence of irra-
diated allogeneic PBMC and PHA, the sorted
cells were stained as above, and results are shown
for the tetramer2 cell fraction (middle) and the
tetramer1 cell fraction (bottom). (C) Each cell
fraction was tested for its lytic activity against
chromium-labeled T2 cells which were sensi-
tized separately with the following HLA-A2–
restricted melanoma-associated peptides: T2 cells
alone (open circles, broken lines), T2 1 gp100 154–
162 (filled circles, broken lines), T2 1 gp100 209–
217 (open triangles, broken lines), T2 1 gp100
280–288 (filled triangles, broken lines), T2 1 gp100
457–466 (open squares), T2 1 gp100 476–485
(filled squares), T2 1 tyrosinase 1–9 (open circles),
T2 1 tyrosinase 368–376 (filled circles), T2 1
Melan-A 26–35 (open triangles), T2 1 MAGE-3
271–279 (filled triangles). (D) The same cell frac-
tions assayed above, unsorted population (open circles), tetramer1 (filled triangles), and tetramer2 (open triangles), were also assayed for their lytic activity against
the autologous tumor cell line, Me 305, derived from the same TILN cell population.1649 Romero et al.
noma-specific CTLs using tetramers may provide new op-
portunities in adoptive immunotherapy.
What Is the Clinical Significance of Strong CTL Responses to
Tumor Antigens? Some patients with high numbers of
Melan-A–specific CTLs have lived for many years free of
tumor, despite evidence of the infiltration of multiple
nodes at surgery. However, it is clear from at least one pa-
tient (LAU 267) that melanoma cells may continue to grow
in the presence of infiltrating tumoricidal CTLs, resulting
in progressive disease. Several mechanisms have already
been proposed for this “tumor escape,” and may pertain to
our data. One possibility is that tumor cells can simply di-
vide faster than CTLs, so that the balance between tumor
progression and immune attack is eventually tilted in the
tumor’s favor. Another well-documented mechanism of
tumor escape is the result of deletions or mutations affect-
ing the genes encoding proteins along the MHC class I
pathway, or the antigen itself (18). Hence, a strong Melan-
A–specific CTL response may be ineffective because the
appropriate MHC class I–peptide complexes are no longer
expressed on the melanoma cell surface. This seems an un-
likely mechanism in many of the cases we studied, since
where autologous melanoma lines could be generated,
these were efficiently lysed by the Melan-A–specific CTLs.
Nevertheless, heterogeneity of tumor cells has been docu-
mented in vivo (19, 20), and escape loss variants may be se-
lected by strong CTL pressure. In one patient (LAU 56),
Melan-A mRNA was not detectable in TILNs which
contained significant numbers of Melan-A–specific CTLs,
although the node was clearly infiltrated with tumor, sug-
gesting Melan-A–negative tumor cells may have been se-
lected for their resistance to CTL lysis. In support of this
interpretation, two subcutaneous metastases resected from
the same patient 4 yr before LN excision were positive for
both Melan-A and tyrosinase mRNA.
Other tumor escape mechanisms have been proposed,
including altered TCR signal transduction or expression
(21), deficient cytokine milieu, and triggering of Fas recep-
tors on CTLs by Fas ligand expressed by tumor cells (22).
In our study, the intense burst of proliferation exhibited by
tumor-specific CTLs upon in vitro culture in the presence
of cytokines, as well as the rapid elimination of autologous
tumor cells from these cultures, suggest that inhibition of
CTL proliferation and/or function in vivo rather than kill-
ing of CTLs by tumor cells could explain the coexistence
of tumor cells and tumor-specific CTLs in TILNs.
Finally, it is worth considering whether various treat-
ment regimes may have contributed to the varying levels
of CTL responses to Melan-A observed in our study, since
several of our patients had been treated with adjuvant
therapy, such as isolated limb perfusion with TNF-a and
melphalan, or systemic IFN-a. Clearly, although chemo-
therapy may have an immunosuppressive effect, adjuvant
therapy with IFNs or TNF-a may have enhanced CTL re-
sponses. However, no simple correlation between treat-
ment modalities and Melan-A–specific CTL responses is
apparent in our study. In this respect, it is conceivable that
longitudinal analyses using tetramers, particularly before
and after therapeutic intervention, may identify effects of
treatment regimens on tumor-specific CTL responses.
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